<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699907</url>
  </required_header>
  <id_info>
    <org_study_id>04-0707-04</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT00699907</nct_id>
  </id_info>
  <brief_title>Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer</brief_title>
  <official_title>A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying samples of blood and tissue in the laboratory from patients with a high risk of
      developing ovarian cancer may help doctors identify and learn more about biomarkers related
      to cancer. We hypothesized that (i) preclinical biologic evidence exists for the role of
      androgens in ovarian cancer development and (ii) flutamide treatment of women at high risk
      for ovarian cancer may identify meaningful tissue biomarkers of androgen action and of
      ovarian cancer initiation. This phase II trial studied the effect of flutamide on biomarkers
      in blood and tissue samples from patients at high risk of ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: Compare the biomarkers of patients at high risk for ovarian cancer who are
      undergoing prophylactic oophorectomy and are interested in taking flutamide vs patients at
      high risk for ovarian cancer who are undergoing prophylactic oophorectomy and are not
      interested in taking flutamide (control) vs patients who are undergoing oophorectomy for a
      medical indication (control).

      OUTLINE: Patients who elected not to receive flutamide received prophylactic oophorectomy or
      oophorectomy for a medical indication. Patients who elected to receive flutamide received
      125mg once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent
      prophylactic oophorectomy. All patients underwent blood and ovarian tissue sample collection
      at the time of surgery for biomarker laboratory studies. Proteomic, microarray, and
      polymorphism analysis were performed on the blood and tissue samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1 levels were measured by immunohistochemistry (IHC).
The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.
The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.
This applies to all measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colony Stimulating Factor (CSF-1) Expression in Ovarian Epithelium</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colony Stimulating Factor (CSF-1) Expression in Ovarian Stroma</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Endosalpingiosis</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Epithelium</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Stroma</measure>
    <time_frame>Surgery</time_frame>
    <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Endosalpingiosis</measure>
    <time_frame>Surgery</time_frame>
    <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Epithelium</measure>
    <time_frame>Surgery</time_frame>
    <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Stroma</measure>
    <time_frame>Surgery</time_frame>
    <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Risk Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
    <description>Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Eulexin</other_name>
    <other_name>Cytomid</other_name>
    <other_name>Cebatrol</other_name>
    <other_name>Chimax</other_name>
    <other_name>Drogenil</other_name>
    <other_name>Flucinom</other_name>
    <other_name>Flutamin</other_name>
    <other_name>Fugerel</other_name>
    <other_name>Niftolide</other_name>
    <other_name>Sebatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all patients:

          -  ≥ 18 years of age

          -  Able to comply with study and follow-up requirements

        Inclusion Criteria for high risk patients:

          -  elected to undergo prophylactic salpingo-oophorectomy

          -  fertile patients must use effective non-hormonal contraception

          -  agreed to use a nonhormonal means of contraception before surgery

          -  serum bilirubin ≤ 1.0 x Upper Limit Normal (ULN), alkaline phosphatase, Aspartate
             Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 2.5 x ULN

          -  serum creatinine ≤ 1.5 x ULN

          -  granulocyte count ≥ 1500/μL

          -  platelet count ≥ 75,000/μL

          -  hemoglobin ≥ 9 g/dL

          -  adequate complete blood count

          -  At high risk for developing ovarian cancer, as defined by any of the following:

          -  Breast Cancer carried a BRCA1 or BRCA2 deleterious mutation, a Lynch syndrome
             mutation, and/or defined by a family history of: 1 first-degree relative with
             epithelial ovarian cancer, ≥1 first-degree female relative with breast cancer when ≤40
             years old, ≥1 first-degree female relative with breast cancer when ≤50 years old, male
             relative with breast cancer, and/or family history of breast cancer or ovarian cancer.

        Inclusion Criteria for low risk patients:

          -  planning to undergo oophorectomy for a medical indication

          -  did not fulfill criteria for high risk of developing ovarian cancer

        Exclusion criteria:

          -  liver disease, current alcohol abuse, or cirrhosis

          -  pregnancy or lactation

          -  current use of hormone therapy

          -  active treatment for cancer

          -  recent, current, or planned participation in another experimental drug study

          -  breast cancer within the past 5 years

          -  significant traumatic injury within the past 6 months

          -  major surgery within the past 6 months

          -  any disease, physical examination findings, or clinical laboratory findings giving
             reasonable suspicion of a disease or condition that contraindicates the continued use
             of an investigational drug or that may render the patient at high risk from treatment
             complication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Setsuko K. Chambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona Arizona Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancerpreventionresearch.aacrjournals.org/content/7/9/896.full</url>
    <description>Cancer Prevention Research, 2014.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902233/</url>
    <description>American Journal of Cancer Research, 2014.</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2018</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian epithelial cancer</keyword>
  <keyword>High risk</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the medical clinic prior to oophorectomy. Participants were recruited from January 2007 until June 2011.</recruitment_details>
      <pre_assignment_details>Participants were assigned to groups immediately after being enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
        </group>
        <group group_id="P2">
          <title>High Risk Arm</title>
          <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
        </group>
        <group group_id="P3">
          <title>Low Risk Arm</title>
          <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No usable sample</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Overall Number of Participants Analyzed represents all participants with a modified Histo-score that could be evaluated</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
flutamide: Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>High Risk Arm</title>
          <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
        </group>
        <group group_id="B3">
          <title>Low Risk Arm</title>
          <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" lower_limit="36" upper_limit="58"/>
                    <measurement group_id="B2" value="46.9" lower_limit="27" upper_limit="66"/>
                    <measurement group_id="B3" value="51.7" lower_limit="21" upper_limit="81"/>
                    <measurement group_id="B4" value="48.9" lower_limit="21" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis</title>
        <description>CSF-1 levels were measured by immunohistochemistry (IHC).
The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.
The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.
This applies to all measures.</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis</title>
          <description>CSF-1 levels were measured by immunohistochemistry (IHC).
The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.
The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.
This applies to all measures.</description>
          <units>Modified H-Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="210"/>
                    <measurement group_id="O2" value="130" lower_limit="0" upper_limit="300"/>
                    <measurement group_id="O3" value="50" lower_limit="5" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Epithelium</title>
        <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Epithelium</title>
          <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="210"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Stroma</title>
        <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor (CSF-1) Expression in Ovarian Stroma</title>
          <description>CSF-1 levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="80"/>
                    <measurement group_id="O2" value="40" lower_limit="5" upper_limit="160"/>
                    <measurement group_id="O3" value="35" lower_limit="5" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Endosalpingiosis</title>
        <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Endosalpingiosis</title>
          <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0" upper_limit="60"/>
                    <measurement group_id="O2" value="160" lower_limit="5" upper_limit="285"/>
                    <measurement group_id="O3" value="75" lower_limit="5" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Epithelium</title>
        <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Epithelium</title>
          <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="160"/>
                    <measurement group_id="O2" value="40" lower_limit="0" upper_limit="270"/>
                    <measurement group_id="O3" value="20" lower_limit="2" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Stroma</title>
        <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Stroma</title>
          <description>CSF-1R levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="O2" value="40" lower_limit="0" upper_limit="210"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Endosalpingiosis</title>
        <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Endosalpingiosis</title>
          <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="O2" value="60" lower_limit="5" upper_limit="270"/>
                    <measurement group_id="O3" value="10" lower_limit="5" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Epithelium</title>
        <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Epithelium</title>
          <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="55" lower_limit="0" upper_limit="270"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Stroma</title>
        <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
        <time_frame>Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O2">
            <title>High Risk Arm</title>
            <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
          </group>
          <group group_id="O3">
            <title>Low Risk Arm</title>
            <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Stroma</title>
          <description>ErbB4 levels were measured by immunohistochemistry (IHC).</description>
          <units>Histo-score (H-Score)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="60"/>
                    <measurement group_id="O2" value="90" lower_limit="10" upper_limit="285"/>
                    <measurement group_id="O3" value="30" lower_limit="10" upper_limit="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.</description>
        </group>
        <group group_id="E2">
          <title>High Risk Arm</title>
          <description>High risk patients underwent risk-reducing salpingo-oophorectomy.</description>
        </group>
        <group group_id="E3">
          <title>Low Risk Arm</title>
          <description>Low risk patients underwent salpingo-oophorectomy for a medical indication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Setsuko K. Chambers</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-0950</phone>
      <email>schamber@uacc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

